Business
Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq
Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA" BERKELEY, Calif, July 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced the closing of its business combination with NorthView Acquisition Corp. (“NVAC”), a special purpos
About this update from Profusa, Inc.
[{"type":"image","alt":"Profusa, Inc.","displaySize":"","headline":null,"caption":"Profusa, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/8f79cba194228307ca23a2955a9ec150"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C0XqXJTHmuw3t23BmCcCpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEyODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8f79cba194228307ca23a2955a9ec150","width":200,"height":71}},"lazy":false},{"type":"text","content":"Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA"","length":124,"tagName":"p"},{"type":"text","content":"BERKELEY, Calif, July 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced the closing of its business combination with NorthView Acquisition Corp. (“NVAC”), a special purpose acquisition company, which was approved by NVAC’s shareholders on June 9, 2025. The combined company will operate under the name Profusa, Inc., with its common stock expected to begin trading on Nasdaq under the ticker symbol “PFSA”, beginning on July 14, 2025. The Company’s warrants will not trade on Nasdaq but rather will continue to trade on the OTCID market.","length":761,"tagName":"p"},{"type":"text","content":"“In a journey that began over a decade ago, driven by a mission to harness transformative science to positively impact quality of daily living and chronic disease management, we are excited to mark a key milestone of going public and trading on Nasdaq. We believe being a public company better positions us to advance our vision in pioneering tissue-integrating biosensors platform that could function for months at a time, with transformative lower costs, and continuously monitor and transmit body chemistries to smart phone applications, and leveraging the best-in-class data analytics and AI technologies, allowing users and healthcare professionals to make real-time actionable decisions that improve general health or manage a chronic disease such as diabetes or critical limb ischemia (CLI), and peripheral arterial disease (PAD),” said B...